Literature DB >> 22285146

Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

Victor de Lédinghen1, Julien Vergniol, Concepcion Gonzalez, Juliette Foucher, Elisa Maury, Louise Chemineau, Sandrine Villars, Henri Gin, Vincent Rigalleau.   

Abstract

BACKGROUND: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to cirrhosis. Existing guidelines do not advocate screening for liver related complications amongst persons with diabetes. AIM: The aim of this prospective study was to identify patients with severe liver fibrosis amongst patients hospitalized for their diabetes, using non-invasive methods, and to evaluate factors associated with severe fibrosis.
METHODS: Consecutive patients with type 1 or 2 diabetes had clinical, biological parameters and liver fibrosis evaluation. Severe fibrosis was predicted when FibroTest was >0.59 or liver stiffness >8.7 kPa.
RESULTS: A total of 277 patients were evaluated (type 1 diabetes 52%). The prevalence of severe fibrosis was 15.5%. By univariate analysis, factors associated with severe fibrosis were age, type 2 diabetes, body mass index, metabolic syndrome, previous cardiovascular events, no retinopathy, past history of foot ulcer, and elevated alanine aminotransferase. By multivariate analysis, factors associated with severe fibrosis were age >50 years, type 2 diabetes, no retinopathy, and past history of foot ulcer.
CONCLUSION: This study showed an elevated prevalence of severe fibrosis in hospitalized diabetic patients, especially patients aged 50 years or older with type 2 diabetes, or with a past history of foot ulcer.
Copyright © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285146     DOI: 10.1016/j.dld.2011.12.005

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  8 in total

Review 1.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

Review 2.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease.

Authors:  Jem Ma Ahn; Yong-Han Paik; So Hyun Kim; Jun Hee Lee; Ju Yeon Cho; Won Sohn; Geum-Youn Gwak; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2014-07-30       Impact factor: 2.153

4.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Marieke de Vries; Jan Westerink; Karin H A H Kaasjager; Harold W de Valk
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

5.  Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study.

Authors:  Jasbir Makker; Hassan Tariq; Kishore Kumar; Madhavi Ravi; Danial Haris Shaikh; Vivien Leung; Umar Hayat; Muhammad T Hassan; Harish Patel; Suresh Nayudu; Sridhar Chilimuri
Journal:  World J Gastroenterol       Date:  2021-02-14       Impact factor: 5.742

6.  Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

Authors:  Thierry Poynard; Olivier Deckmyn; Mona Munteanu; Yen Ngo; Fabienne Drane; Jean Marie Castille; Chantal Housset; Vlad Ratziu
Journal:  BMJ Open       Date:  2015-12-23       Impact factor: 2.692

7.  Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Authors:  Fernando Bril; Michael J McPhaul; Michael P Caulfield; Jean-Marie Castille; Thierry Poynard; Consuelo Soldevila-Pico; Virginia C Clark; Roberto J Firpi-Morell; Jinping Lai; Kenneth Cusi
Journal:  J Investig Med       Date:  2018-10-10       Impact factor: 2.895

8.  Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

Authors:  Olivier Deckmyn; Thierry Poynard; Pierre Bedossa; Valérie Paradis; Valentina Peta; Raluca Pais; Vlad Ratziu; Dominique Thabut; Angelique Brzustowski; Jean-François Gautier; Patrice Cacoub; Dominique Valla
Journal:  Biomedicines       Date:  2022-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.